How The UK Regulatory System Would Work In A No-Deal Brexit – Part 1
Regulations that would allow the UK MHRA to work as a standalone regulator in the event of a no-deal Brexit have been laid before parliament. They cover a host of areas including new drug approval procedures, conversion of existing EU marketing authorizations into UK ones, pediatric and orphan exclusivities, imported medicines, and regulatory fees.
You may also be interested in...
Draft regulations on medicines and medical devices could get caught up in the chaos that seems about to engulf the UK parliament as opposition MPs attempt to avert a no-deal Brexit.
The MHRA highlighted at a recent conference in India the key changes that await pharma in the event of a no-deal Brexit, and the agency’s general readiness in that scenario, including putting in place its own IT systems such as a UK national replacement for the EudraGMDP.
MHRA pharmacovigilance leader says global safety efforts will not lose UK expertise.